C. M. R. Lima

发表

Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.

G. Shapiro, T. Owonikoko, M. Thomas, 2017 .

Abstract CT151: G1T28, a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin for extensive stage small cell lung cancer (ES-SCLC): preliminary results

M. Thomas, P. Roberts, V. Priego, 2016 .

A Phase II Trial of Perifosine in Locally Advanced, Unresectable, or Metastatic Pancreatic Adenocarcinoma

A. Benson, K. Rowland, E. Mitchell, 2007, American journal of clinical oncology.

D.I.G. — Phase I trial of sequential administration of docetaxel (D) followed 24 hs by gemcitabine (G) and irinotecan (I) in patients with solid tumors

Mark R. Green, A. Safa, C. Catapano, 2000 .

Gefitinib ( ZD 1839 ) in Previously Treated Advanced Non – Small-Cell Lung Cancer : Experience From a Single Institution

G. Bepler, A. Cantor, E. Haura, 2003 .

Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.

C. M. R. Lima, 2018, Clinical advances in hematology & oncology : H&O.

Adjuvant Therapy in Non-Small Cell Lung Cancer

Mark R. Green, S. Leong, C. Lima, 1999 .

Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.

G. Narayanan, D. Sleeman, A. Ribeiro, 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Addition of algenpantucel-L immunotherapy to standard of care (SOC) adjuvant therapy for pancreatic cancer.

M. Talamonti, H. Lenz, M. Mulcahy, 2012 .

A retrospective study of neoadjuvant DCF (docetaxel, cisplatin, 5-fluorouracil) for locally advanced gastric or gastro-esophageal junction adenocarcinoma (GC).

P. Hosein, L. Portelance, U. Bayraktar, 2013 .

Correlation of anti-calreticulin antibody titers with improved overall survival in a phase 2 clinical trial of algenpantucel-L immunotherapy for patients with resected pancreatic cancer.

M. Talamonti, H. Lenz, M. Mulcahy, 2014 .

Comparison of Cancer Care and Outcomes between a Public Safety-Net Hospital and a Private Cancer Center

U. Bayraktar, E. Chen, S. Warsch, 2013, Journal of health care for the poor and underserved.

Prevalence of radiologic evidence of metastatic pancreatic ductal adenocarcinoma (PDAC) at first post-operative restaging studies in patients (pts) undergoing pancreatic cancer surgery with curative intent.

I. Reis, P. Hosein, J. Merchan, 2016 .

A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC).

C. Fuchs, H. Safran, E. Feigal, 2010 .

Phase II trial of paclitaxel-topotecan-etoposide (PTE) followed by consolidation chemoradiotherapy for limited stage small cell lung cancer (LS-SCLC): CALGB 30002

Michael R. Green, E. Vokes, J. Bogart, 2005 .

Phase II Trial of Paclitaxel–Topotecan–Etoposide Followed by Consolidation Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer: CALGB 30002

E. Vokes, Mark R. Green, J. Bogart, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instabili

N. Wolmark, P. Ganz, S. Kopetz, 2021, Journal of Clinical Oncology.

1496TiP Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma

R. Greil, F. Lordick, V. Heinemann, 2020 .

Comparison of survival for metastatic pancreatic cancer patients treated with CPI‐613 versus resected borderline‐resectable pancreatic cancer patients

C. Clark, P. Shen, C. Valenzuela, 2023, Journal of surgical oncology.

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors

G. Shapiro, H. Hurwitz, T. Busman, 2014, Investigational New Drugs.

Effect of hyperacute immunotherapy in addition to standard adjuvant therapy for resected pancreatic cancer on disease-free and overall survival: Preliminary analysis of phase II data.

M. Talamonti, M. Mulcahy, C. Link, 2010 .

Radiation and chemotherapy for patients with stage III non-small cell lung cancer.

Mark R. Green, M. Green, C. Sherman, 2000, Seminars in radiation oncology.

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

T. Owonikoko, P. Roberts, J. Hamm, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine (G)-based therapy.

P. Bejarano, G. Lopes, I. Reis, 2010 .

Phase II trial of capecitabine and docetaxel as second line therapy for locally advanced and metastatic pancreatic cancer

E. Roman, G. Lopes, M. Green, 2007 .